| 0.7389 -0.045 (-5.74%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.98  |
1-year : | 1.08 |
| Resists | First : | 0.84 |
Second : | 0.93 |
| Pivot price | 0.81 |
|||
| Supports | First : | 0.71 |
Second : | 0.59 |
| MAs | MA(5) : | 0.78 |
MA(20) : | 0.82 |
| MA(100) : | 1.12 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 14.6 |
D(3) : | 20 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 2.56 | Low : | 0.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XTLB ] has closed below the lower bollinger band by 4.6%. Bollinger Bands are 65.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.79 - 0.79 | 0.79 - 0.8 |
| Low: | 0.7 - 0.7 | 0.7 - 0.71 |
| Close: | 0.73 - 0.74 | 0.74 - 0.74 |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Wed, 24 Dec 2025
XTL Biopharmaceuticals Limited Receives Nasdaq Notification of Bid Price Deficiency, Plans to Regain Compliance - Quiver Quantitative
Fri, 05 Dec 2025
XTL Biopharmaceuticals appoints Niv Segal as new chief financial officer - Investing.com
Thu, 23 Oct 2025
XTL Biopharmaceuticals appoints CEO Noam Band to board after director resignation - Investing.com
Wed, 08 Oct 2025
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Wed, 08 Oct 2025
XTL Biopharmaceuticals Price Skyrockets: Buy or Bail? - timothysykes.com
Wed, 08 Oct 2025
XTL Biopharmaceuticals: Shifting Gears or Grounded Reality? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 452 (M) |
| Held by Insiders | 41.2 (%) |
| Held by Institutions | 2.6 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -227.8 % |
| Operating Margin | -200.5 % |
| Return on Assets (ttm) | -24.8 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -2.47 |
| PEG Ratio | 0 |
| Price to Book value | 73.88 |
| Price to Sales | 14.43 |
| Price to Cash Flow | -4.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|